Literature DB >> 1279001

Complement system in pneumococcal infections.

W P Reed, M S Davidson, R C Williams.   

Abstract

The properdin or alternate complement pathway may function as a heat-labile opsonin for pneumococci, and evidence has been sought for its activation in pneumococcal infections. Twenty-two patients had determinations of C1q, C4, properdin factor B, C3, and hemolytic complement during hospitalization for pneumococcal infection. Measurements were made during the first 36 h after admission on 16 patients and later during recovery on 16. The admission and recovery values were compared statistically with each other and with the levels of 15 normal individuals. The admission and recovery mean values were normal and nearly identical for C1q and C4, which are two early components of the classical pathway. The mean level of factor N, a properdin pathway component, was significantly depressed on admission, but the mean recovery value was normal. Admission levels for C3, a component of the late common pathway, were depressed, and recovery values were normal. Total hemolytic complement was decreased on admission, although the decrease was not significant for the patients with both admission and recovery determinations. The findings are consistent with the hypothesis that factor B is turned over rapidly, or consumed, early in pneumococcal infections; alternatively, persons with low baseline factor B levels may be particularly susceptible to pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1279001      PMCID: PMC420727          DOI: 10.1128/iai.13.4.1120-1125.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  Pneumococcal type-associated variability in alternate complement pathway activation.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

2.  Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Authors:  J A Winkelstein; H S Shin; W B Wood
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

3.  Deficiency of pneumococcal serum opsonizing activity in sickle-cell disease.

Authors:  J A Winkelstein; R H Drachman
Journal:  N Engl J Med       Date:  1968-08-29       Impact factor: 91.245

4.  Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3).

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

5.  C3 proactivator (C3PA) as an acute phase reactant.

Authors:  M Schutte; R DiCamelli; P Murphy; M Sadove; H Gewurz
Journal:  Clin Exp Immunol       Date:  1974-10       Impact factor: 4.330

6.  Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level.

Authors:  L H Perrin; P H Lambert; U E Nydegger; P A Miescher
Journal:  Clin Immunol Immunopathol       Date:  1973-11

Review 7.  Opsonins: their function, identity, and clinical significance.

Authors:  J A Winkelstein
Journal:  J Pediatr       Date:  1973-05       Impact factor: 4.406

8.  An abnormality of the alternate pathway of complement activation in sickle-cell disease.

Authors:  R B Johnston; S L Newman; A G Struth
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

9.  The role of immunoglobulin in the interaction of pneumococci and the properdin pathway: evidence for its specificity and lack of requirement for the Fc portion of the molecule.

Authors:  J A Winkelstein; H S Shin
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

Review 10.  Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature.

Authors:  E Barrett-Connor
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

View more
  17 in total

1.  Effects of pneumococcal mucopeptide and capsular polysaccharide on phagocytosis.

Authors:  R K Dhingra; R C Williams; W P Reed
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

2.  Effect of temperature on bacterial killing by serum and by polymorphonuclear leukocytes.

Authors:  J Sebag; W P Reed; R C Williams
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

3.  Classical and alternative complement pathway activation by pneumococci.

Authors:  C G Stephens; R C Williams; W P Reed
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

4.  Complement activating factor(s) of Trypanosoma lewisi: some physiochemical characteristics of the active components.

Authors:  K Nielsen; J Sheppard; I Tizard; W Holmes
Journal:  Can J Comp Med       Date:  1978-01

5.  Interaction of pneumococcal antigens with complement in rats.

Authors:  J D Coonrod; S Jenkins
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

6.  Complement levels in pneumococcal pneumonia.

Authors:  J D Coonrod; B Rylko-Bauer
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

7.  Activation of human complement by the pneumococcal toxin pneumolysin.

Authors:  J C Paton; B Rowan-Kelly; A Ferrante
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  Alterations in serum opsonic activity and complement levels in pneumococcal disease.

Authors:  G S Giebink; T H Dee; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

9.  Reduction of circulating granulocytes induced by type 1 pneumococcal cell walls in New Zealand white rabbits.

Authors:  S E Goldblum; W P Reed; L L Barton
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

10.  Gram-positive bacteria-induced granulocytopenia and pulmonary leukostasis in rabbits.

Authors:  S E Goldblum; W P Reed
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.